Andrew Evans

Dr. Andrew Evans

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2007 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
AEAndrew Evans
Andrew Evans
VBVictoria Bates
Victoria Bates
HTHelen Troy
Helen Troy
SHStephen M Hewitt
Stephen M Hewitt
SHSusan Holbeck
Susan Holbeck
RARachel Airley
Rachel Airley

1 December 2018 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
PSPeter Segun
Peter Segun
FIFyaz Ismail
Fyaz Ismail
OOOmonike O. Ogbole
Omonike O. Ogbole
Lutfun NaharLutfun Nahar
Lutfun Nahar
AEAndrew Evans
Andrew Evans
Satyajit SarkerSatyajit Sarker
Satyajit Sarker

1 January 2015 in Journal of Cancer
Verified
Journal Article
Open access
JPjonai pujol
jonai pujol
FHFátima Perez de Heredia
Fátima Perez de Heredia
Miguel A. IdoateMiguel A. Idoate
Miguel A. Idoate
RARachel Airley
Rachel Airley
MLMaria Pilar Lostao
Maria Pilar Lostao
AEAndrew Evans
Andrew Evans
Background: Recent studies proposed GLUT12 to be a major glucose transporter involved in the glycolytic metabolism of cancer cells.

16 March 2016 in Cell and tissue research
Verified
Journal Article
Open access
PDF file
SSSikander Sharma
Sikander Sharma
AEAndrew Evans
Andrew Evans
EHElaine Hemers
Elaine Hemers
Glucose deprivation, hypoxia and acidosis are characteristic features of the central core of most solid tumours. Myofibroblasts are stromal cells present in many such solid tumours, including those of the colon, and are known to be involved in all stages of tumour progression. HMGB1 is a nuclear protein with an important role in nucleosome stabilisation and gene transcription; it is also released from immune cells and is involved in the inflammatory process. We report that the microenvironmental condition of glucose deprivation is responsible for the active release of HMGB1 from various types of cancer cell lines (HT-29, MCF-7 and A549) under normoxic conditions. Recombinant HMGB1 (10 ng/ml) triggered proliferation in myofibroblast cells via activation of PI3K and MEK1/2. Conditioned medium collected from glucose-deprived HT-29 colon cancer cells stimulated the migration and invasion of colonic myofibroblasts, and these processes were significantly inhibited by immunoneutralising antibodies to HMGB1, RAGE and TLR4, together with specific inhibitors of PI3K and MEK1/2. Our data suggest that HMGB1 released from cancer cells under glucose deprivation is involved in stimulating colonic myofibroblast migration and invasion and that this occurs through the activation of RAGE and TLR4, resulting in the activation of the MAPK and PI3K signalling pathways. Thus, HMGB1 might be released by cancer cells in areas of low glucose in solid tumours with the resulting activation of myofibroblasts and is a potential therapeutic target to inhibit solid tumour growth.

13 February 2018 in Molecules
Verified
Journal Article
Open access
PDF file
STStephanie Guetchueng Tamdem
Stephanie Guetchueng Tamdem
Lutfun NaharLutfun Nahar
Lutfun Nahar
KRKenneth J. Ritchieb
Kenneth J. Ritchieb
FIFyaz Ismail
Fyaz Ismail
AEAndrew Evans
Andrew Evans
Satyajit SarkerSatyajit Sarker
Satyajit Sarker
New clerodane diterpenes, 12-epi-megalocarpodolide D (2) and an epimeric mixture of crotonolins A (3) and B (4), were isolated from the bark of Croton oligandrus following a bioassay-guided isolation protocol. Known compounds, megalocarpodolide D (1), 12-epi-crotocorylifuran (5), cluytyl-ferulate (6), hexacosanoyl- ferulate (7), vanillin (8), acetyl-aleuritolic acid (9) and lupeol (10), were also isolated. The structures of the isolated compounds (1–10) were elucidated by spectroscopic means. The cytotoxicity of compounds 1–10 was assessed against A549, MCF7, PC3 and PNT2 cell lines using the MTT assay. Compounds 1 and 2 showed moderate levels of activity against both A549 and MCF7 cells with 1 being the most active with IC50 values of 63.8 ± 13.8 and 136.2 ± 22.7 µM against A549 and MCF7 cells, respectively. The epimeric mixture of 3 and 4 was moderately active against A549 and PC3 cells (IC50 = 128.6 ± 31.0 and 111.2 ± 2.9 µM, respectively).

1 August 2018 in Phytochemistry Letters
Verified
Journal Article
Closed access
SGStephanie T. Guetchueng
Stephanie T. Guetchueng
Lutfun NaharLutfun Nahar
Lutfun Nahar
KRKenneth J. Ritchie
Kenneth J. Ritchie
FIFyaz Ismail
Fyaz Ismail
AEAndrew Evans
Andrew Evans
SSSatyajit D. Sarker
Satyajit D. Sarker